Vilstrup Frida, Sivapalan Pradeesh, Eklöf Josefin, Jordan Alexander, Biering-Sørensen Tor, Sperling Søren, Jensen Jens-Ulrik Stæhr
Department of Medicine, Section of Respiratory Medicine, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, 2900, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2200, Denmark.
Int J Chron Obstruct Pulmon Dis. 2025 May 21;20:1585-1593. doi: 10.2147/COPD.S496676. eCollection 2025.
Patients with chronic obstructive pulmonary disease (COPD) are a heavily comorbid group. Quinine is often used in the treatment of restless leg syndrome (RLS), although the adverse effects of the drug may be harmful for specific patient groups. The aim of this study was to determine the association between treatment with Quinine and the risk of acute exacerbations and mortality in patients with COPD, which has not previously been investigated.
Analyses were performed on data from Danish national registries containing information about the relevant patients and their health, prescriptions, hospital admissions, and outpatient clinic visits. A propensity score matched cohort was created by matching the population on known predictors of the outcome, and an unadjusted Cox proportional hazards regression analysis was performed. Lastly, a multivariable Cox analysis was performed on the entire, unmatched population, adjusting for the same variables as used in the propensity matching.
The study population consisted of a cohort of 56,691 eligible patients with COPD, of whom 3,139 were exposed to Quinine. The propensity score matching led to two groups of 2,537 COPD patients, where one group was exposed to Quinine (cases) and the other group was not (controls). Exposure to Quinine was associated with an increased risk of exacerbations or death in a sensitivity analysis of the propensity-score-matched population (Hazard Ratio (HR) 1.130, 95% Confidence Interval (CI) 1.03 to 1.24). An unadjusted analysis on the unmatched population showed similar results (HR 1.475, 95% CI 1.39 to 1.56).
In the current study, we found an association between the use of Quinine in patients with COPD and an increased risk of acute exacerbations and death. The results must be interpreted with attention to the observational nature of the study, and in order to definitively determine the association, further investigations should be performed.
慢性阻塞性肺疾病(COPD)患者常伴有多种合并症。奎宁常用于治疗不宁腿综合征(RLS),尽管该药物的不良反应可能对特定患者群体有害。本研究的目的是确定奎宁治疗与COPD患者急性加重和死亡风险之间的关联,此前尚未对此进行过研究。
对丹麦国家登记处的数据进行分析,这些数据包含有关相关患者及其健康状况、处方、住院和门诊就诊的信息。通过根据已知的结果预测因素对人群进行匹配,创建了一个倾向评分匹配队列,并进行了未调整的Cox比例风险回归分析。最后,对整个未匹配人群进行多变量Cox分析,对与倾向匹配中使用的相同变量进行调整。
研究人群包括56,691名符合条件的COPD患者队列,其中3,139人接触过奎宁。倾向评分匹配产生了两组各2,537名COPD患者,一组接触奎宁(病例组),另一组未接触(对照组)。在倾向评分匹配人群的敏感性分析中,接触奎宁与加重或死亡风险增加相关(风险比(HR)1.130,95%置信区间(CI)1.03至1.24)。对未匹配人群的未调整分析显示了类似结果(HR 1.475,95%CI 1.39至1.56)。
在本研究中,我们发现COPD患者使用奎宁与急性加重和死亡风险增加之间存在关联。必须注意到该研究的观察性本质来解释结果,为了明确确定这种关联,应进行进一步调查。